Ann: IMU Meets Endpoints in Phase 1b Gastric Cancer Trial, page-72

just have to be patient
neither (being VLA or IMU) are really available on the nasdaq minus pink sheet OTC which are almost impossible for most people to buy

so opens the door to all sort of nonsense

plus the markets are just shot
bio will be a safe place to a degree if industries hit the fan in the old days biotech was always a reverse safety trade of the markets but doesn't seem to work that way any more

there is a ton of info here if anyone wants to read up about it most is beyond my comprehension https://www.esmo.org/Guidelines/Bre...s-Guidelines-for-Advanced-Breast-Cancer-ABC-4

this was interesting to read though

Furthermore, in several countries, anti-HER2 therapy, namely trastuzumab,(Herceptin) can only be used once in the metastatic setting since its use beyond progression is either not approved or not reimbursed; in those cases, preference should be given to a combination of ChT plus anti-HER2 therapy in view of the OS benefit observed.

cheers have a good one